EFPIA statement on the EU Strategy on COVID Therapeutics

EFPIA welcomes today’s publication of the EU Strategy on COVID Therapeutics.  The strategy underlines the importance of therapeutics in mitigating the impact of COVID-19 on people, on health systems and on society. 
While vaccination programmes continue to scale up around the world, therapeutics play a key role in saving lives, freeing up capacity in intensive care units and treating patients living with long-COVID.
We welcome the strategy’s bench to bedside approach covering research, development and innovation, including scanning for candidate therapeutics as well as access to and swift approval of clinical trials, regulatory flexibility, supply chains, international cooperation and joint procurement and financing.
EFPIA members are working around the clock to develop new tools to help patients and clinicians fight COVID-19. There are currently nearly 3000 clinical trials exploring therapeutics for treating COVID patients[1] and around 61 therapeutic candidates such anti-virals, anti- monoclonal antibodies, anti-hypertensives, anti-inflammatories, immunomodulators, antithrombotics and steroids in the latter stages of development.[2] 
EFPIA and its members are committed to working with the EU Institutions and Member States to accelerate the continued development, delivery and availability of therapeutics for the use in the fight against COVID-19 in Europe and around the world.

[2] Airfinity Ltd. 05-05-2021